Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept in Advanced Solid Tumors and Lymphoma
NCT03013218Phase 1Completed
- Sponsor
- ALX Oncology
- Start
- Feb 2017
- Primary completion
- Feb 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of evorpacept in solid tumor, non-Hodgkin lymphoma (NHL), head and neck squamous cell carcinoma (HNSCC) and 2 more (6 arms), sponsored by ALX Oncology. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Feb 2017; status: completed.
02
Drugs
evorpacept
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)head and neck squamous cell carcinoma (HNSCC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03013218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013218.